These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37400175)

  • 1. Fundamentals of utilizing microbes in advanced cancer therapeutics: current understanding and potential applications.
    Kaur T; Sharma D
    Adv Appl Microbiol; 2023; 123():91-131. PubMed ID: 37400175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viruses: what to expect from their use in cancer treatment.
    Terrível M; Gromicho C; Matos AM
    Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
    Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From virotherapy to oncolytic immunotherapy: where are we now?
    Coffin RS
    Curr Opin Virol; 2015 Aug; 13():93-100. PubMed ID: 26121656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viruses for cancer immunotherapy.
    Hemminki O; Dos Santos JM; Hemminki A
    J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy.
    Sun M; Yang S; Huang H; Gao P; Pan S; Cheng Z; He Z; Wang Z; Sun J; Liu F
    Nano Lett; 2022 Jun; 22(12):5055-5064. PubMed ID: 35583490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy: Challenges and solutions.
    Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
    Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
    Kontermann RE; Ungerechts G; Nettelbeck DM
    MAbs; 2021; 13(1):1982447. PubMed ID: 34747345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic polio virotherapy of cancer.
    Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
    Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: A new target for cancer cure (Review).
    Zhao F; Shen D; Shang M; Yu H; Zuo X; Chen L; Huang Z; Li L; Wang L
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of viruses in cancer development versus cancer therapy: An oncological perspective.
    Javid H; Sharbaf Mashhad A; Yazdani S; Akbari Oryani M; Akbari S; Rezagholinejad N; Tajaldini M; Karimi-Shahri M
    Cancer Med; 2023 May; 12(10):11127-11148. PubMed ID: 36880311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).
    Wang X; Zhong L; Zhao Y
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33760203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
    Bauzon M; Hermiston TW
    Curr Opin Mol Ther; 2008 Aug; 10(4):350-5. PubMed ID: 18683099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.